futrafur (UFT)/cisplatin (CDDP) [2] From November 4, 1999 to February 22, 2000, six cycles of combined chemotherapy with irinotecan (CPT-11)/CDDP [3] were administered every 2 weeks ; total dose, CPT-11, 418 mg; CDDP, 184 mg). The results showed a partial response (PR; duration of response, 59 days) on computed tomography (CT) images, followed by both increased levels of tumor markers and the occurrence of abdominal lymph node enlargement.
From February 29 to May 16, 2000 , the TS-1 (1 M tegafur-0.4 M gimeracil-1 M oteracil potassium) regimen was carried out at 80-100 mg/day, being administered on days 1-28, then discontinued for 14 days, for a total dose of TS-1 of 5440 mg) [4] . The results showed minor response (MR) on CT images, but, on May 16, 2000, the patient developed a metastatic focus in the right cervical lymph node (newly developed lesion).
From May 19 to July 11, 2000, time-lag alternating administration of methotrexate (MTX)/fluorouracil (5-FU) [5] was conducted every 2 weeks (MTX, 140 mg/ body; 5-FU, 840 mg/body, with calcium folinate added as a toxicity-reducing measure. Total dose, MTX, 700 mg; 5-FU, 4200 mg). Results included: enlargement of abdominal lymph node; on July 25, 2000, a newly developed metastasis on the right axillary lymph node; and, at the same time, the patient's general condition worsened, according to the Eastern Cooperative Oncology Group (ECOG) performance status (PS), from grade 0 to 2, indicating progressive disease (PD).
Courses of combined chemotherapy with 5Ј-DFUR/docetaxel (Figs. 1, 2)
From July 18, 2000, combined chemotherapy with 5Ј-DFUR/docetaxel was started. One course of the regimen consisted of 5Ј-DFUR, 1000 mg/body (700 mg/m 2 ), oral administration for 2 consecutive weeks (days 1-14), discontinuation of the regimen for a week; and docetaxel, 80 mg/body (60 mg/m 2 ) administered by intravenous drip on day 8, every 3 weeks. After two courses of this regimen, the results showed 81% reduction of the abdominal lymph node tumor (from 5.0 ϫ 4.3 to 3.5 ϫ 3.7 cm) and 40% reduction of the right cervical lymph node tumors (from 2.9 ϫ 2.6 and 3.4 ϫ 2.7 to 1.7 ϫ 1.3 and 1.0 ϫ 0.9 cm). A further three courses of the regimen were given, resulting in approximately 90% reduction of the abdominal lymph node (1.1 ϫ 0.8 to 1.2 ϫ 0.7 cm) and disappearance of the right cervical lymph node ( Fig. 2A, B) . The results also showed reductions in levels of two tumor markers (carcinoembryonic antigen [CEA] and carbohydrate antigen [CA]19-9), and improvements in his general condition from grade 2 before drug administration to grade 0 from the second course. The abdominal lymph node reduction and right cervical lymph node disappearance persisted. However, from January 2001, bone marrow metastasis worsened and left hydronephrosis appeared. Thus, the condition of disease was evaluated as aggravated, and the combined drug administration was terminated after seven courses in total. The final response period lasted for 126 days; the patient died on day 298 after starting this combined regimen. As for hematological toxicity, leukocytopenia (grade 2) and neutropenia (grade 4) appeared from day 7 of the treatment, for which granulocyte colonystimulating factor (G-CSF) was used in every course of the drug administration. Although a decrease in hemoglobin level (grade 2) was observed from day 7 of the treatment, no blood transfusion was conducted. Nonhematological toxicity included fever (grade 1), fatigue (grade 2), dysgeusia (grade 2), alopecia (grade 2), anorexia (grade 1), and nausea (grade 1). To control these toxicities, the patient was given an oral steroid, which decreased fever, fatigue, anorexia, and nausea. All other adverse events were within permissible limits. Efficacy of the combined regimen was assessed according to the "General rules for gastric cancer study" of the Japanese Research Society for Gastric Cancer (1995) [6] , and toxicity associated with the regimen was evaluated according to the National Cancer Institute Common Toxicity Criteria, Version 2.0 (NCI-CTC, ver. 2.0) [7] . The patient was sufficiently advised of the combined drug treatment and his informed consent was obtained before the start of therapy.
Discussion
Docetaxel is a newly developed anticancer drug that has a mechanism of action to promote tubulin polymerization and to inhibit the depolymerization of microtubules. In a phase II study conducted in Japan with the drug for patients with advanced gastric cancer, 80 mg/ body (60 mg/m 2 ) of docetaxel was given to the patients by drip infusion once every 3 to 4 weeks. The results showed a response rate of 23.7% (14/59 patients). 5Ј-Deoxy-5-fluorouridine; (generic name, doxifluridine; 5Ј-DFUR), which is a prodrug and an intermediate metabolite of capecitabine, is converted by pyrimidine nucleoside phosphorylase (PyNPase) to 5-FU and shows antitumor activity [8, 9] . In a phase II study conducted in Japan, 5Ј-DFUR was given orally to gastric cancer patients at repeated doses of 800-1200 mg/day. The results showed a response rate of 14.3% (20/140 patients) [10] . The drug was also shown to be useful in treating patients with other solid cancers [11] [12] [13] [14] [15] .
In a recent basic study, docetaxel and several other anticancer drugs reportedly induced thymidine phosphorylase (TP), one type of PyNPase, in tumor tissues [16] . Furthermore, in tumors showing induced levels of TP, concomitant administration of docetaxel and 5Ј-DFUR demonstrated a stronger synergistic efficacy than had been observed when other drugs were used. Animal studies comparing the effects of drug regimens, including 5Ј-DFUR, administered consecutively for 14 days, and combined single administrations of docetaxel on days 1, 8, or 15 showed that the strongest inhibitory effect on tumor growth occurred with the combined regimen on day 8 [17, 18] . Based on this finding, clinical phase II and III studies were conducted in the breast cancer field, in which 5Ј-DFUR (14 consecutive days' administration) combined with docetaxel (administered on day 8) was repeatedly given every 3 weeks. From these results, it was recommended to administer the two drugs at the respective doses of 800 mg/day and 60 mg/m 2 . We employed this combined regimen for the present patient with advanced recurrent gastric cancer, and we obtained good results. This patient had received various anticancer drugs, including 5-FU and its derivatives, in previous regimens. Although shrinkage of tumors was identified, every one of them progressed to regrowth. It should be noted, however, that with this combined regimen, the patient showed a reduction of tumor size and improvement of his general condition. Yet, on the other hand, it was not clear why the combined treatment with 5Ј-DFUR/docetaxel showed efficacy. This result may be related to findings reported by basic studies whereby TP was induced by docetaxel [16] or the apoptosis-relating factor, Bcl2/Bax ratio, was reduced by capecitabin/5Ј-DFUR [19] , both of which could enhance the antitumor effects of 5Ј-DFUR and docetaxel when used concomitantly. In the present, patient, because 5-FU or its derivatives had been administered in the previous three regimens, it may be assumed that docetaxel was responsible for the response of the patient, but at the same time, synergistic effects with fluorouracil may also be assumed to be responsible for the response.
Although the usefulness of anticancer drug treatment in patients with gastric cancer has been proven, the level of the sustained effect in prolonging life with anticancer drugs is insufficient. It is thus essential to establish more effective drug regimens and to introduce effective treatment for patients that show resistance to anticancer drugs. The present report suggests significant clinical evidence to support the idea that a combined regimen with 5Ј-DFUR/docetaxel could be an effective postoperative treatment for patients with advanced gastric cancer. But it should be noted at the same time that the present patient developed grade 4 neutropenia during every drug administration course; thus, patients receiving the combined drug therapy should be sufficiently monitored during the treatment courses. On the basis of the concept described above, we are conducting a clinical phase I study.
